Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 10/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 10/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 9/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 9/20 | 0.56 |
| ▸ | HDAC7 | Q8WUI4 | 9/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 9/20 | 0.56 |
| ▸ | HDAC10 | Q969S8 | 9/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 9/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 9/20 | 0.56 |
| ▸ | HDAC9 | Q9UKV0 | 9/20 | 0.56 |
| ▸ | HDAC5 | Q9UQL6 | 9/20 | 0.56 |
| ▸ | F10 | P00742 | 2/20 | 0.53 |
| ▸ | BCHE | P06276 | 2/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.50 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.49 |
| ▸ | ACACB | O00763 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10194570 | 0.91 | F10 (0.55) | HDAC1HDAC6HDAC3HDAC4HDAC7 | |
| SCHEMBL8349036 | 0.89 | HDAC6 (0.68) | HDAC1HDAC6HDAC3HDAC4HDAC7 | |
| SCHEMBL10194640 | 0.87 | HDAC6 (0.60) | HDAC1HDAC6HDAC3HDAC4HDAC7 | |
| SCHEMBL10194493 | 0.86 | F10 (0.51) | HDAC1HDAC6HDAC3HDAC4HDAC7 | |
| SCHEMBL10194627 | 0.86 | HDAC8 (0.59) | HDAC1HDAC6HDAC3HDAC4HDAC7 | |
| SCHEMBL12933259 | 0.84 | HDAC3 (0.51) | HDAC1HDAC6HDAC3HDAC4HDAC7 | |
| SCHEMBL10194572 | 0.83 | F10 (0.45) | HDAC1HDAC6HDAC3HDAC4HDAC7 | |
| SCHEMBL10194599 | 0.83 | HDAC6 (0.56) | HDAC1HDAC6HDAC3HDAC4HDAC7 | |
| SCHEMBL10194633 | 0.83 | HDAC3 (0.60) | HDAC1HDAC6HDAC3HDAC4HDAC7 | |
| SCHEMBL8222113 | 0.82 | HDAC1 (0.77) | HDAC1HDAC6HDAC3HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513237-B2 | Sulfonylamino-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-08-20 | — | — | US | disclosed |
| US-20120178741-A1 | Sulfonylamino-Derivatives As Novel Inhibitors Of Histone Deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-07-12 | — | — | US | disclosed |
| US-8163733-B2 | Sulfonylamino-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-04-24 | — | — | US | disclosed |
| US-8163733-B2 | Sulfonylamino-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-04-24 | — | — | US | disclosed |
| US-7868205-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2011-01-11 | — | — | US | disclosed |
| US-7868205-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2011-01-11 | — | — | US | disclosed |
| US-20100234353-A1 | SULFONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234353-A1 | SULFONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-09-16 | — | — | US | disclosed |
| US-7767679-B2 | Sulfonylamino-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-08-03 | — | — | US | disclosed |
| US-7767679-B2 | Sulfonylamino-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-08-03 | — | — | US | disclosed |
| US-20080132459-A1 | Inhibitors of Histone Deacetylase | METHYLGENE, INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| US-20080132459-A1 | Inhibitors of Histone Deacetylase | METHYLGENE, INC. (CA) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234353-A1 | SULFONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC3, HDAC11 | HDAC1 1/4885HDAC6 11/4885HDAC3 2/4885 |
| US-20080132459-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC5, HDAC3 | HDAC1 1/4885HDAC6 6/4885HDAC3 3/4885 |
| US-20120178741-A1 | Sulfonylamino-Derivatives As Novel Inhibitors Of Histone Deacetylase | HDAC1, HDAC3, HDAC11 | HDAC1 1/4885HDAC6 11/4885HDAC3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.